News
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).
Both companies offer
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).
Both companies offer
Where Will Viatris Be in 5 Years?
Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has
Where Will Viatris Be in 5 Years?
Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss
2 Beaten-Down Dividend Stocks to Buy
Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it
2 Beaten-Down Dividend Stocks to Buy
Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and
Is Viatris Stock Good for Dividend Income?
Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines
Is Viatris Stock Good for Dividend Income?
Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out
Viatris Stock: Bull vs. Bear
Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec
Viatris Stock: Bull vs. Bear
Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and
Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their
Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their
Why Amarin Stock Is Sinking Today
Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on
Better High-Yield Dividend Stock: Altria or Viatris?
If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of
Better High-Yield Dividend Stock: Altria or Viatris?
If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof